A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens The objective of this study is to determine whether therapy with rituximab alters the immune response in relapsed or refractory, low-grade or follicular, CD20+, B-cell NHL subjects in comparison to un...

• Country None
• organs None
• Specialty None

An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803 To determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have complet...

• Country None
• organs None
• Specialty None

Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) The primary objective of the study is to evaluate the long-term safety profile of dexpramipexole in subjects with ALS.

• Country None
• organs None
• Specialty None

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa The primary objective of the study is to assess the preliminary safety and tolerability of single and multiple oral doses of BIIB014 when administered as adjunct therapy in subjects with moderate to l...

• Country None
• organs None
• Specialty None

A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) To explore whether mefloquine can delay or stop progression of PML as measured by JCV levels in CSF.

• Country None
• organs None
• Specialty None

Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Subjects Impacto de natalizumab frente a fingolimod en lesiones del tejido del sistema nervioso central y en la recuperación de sujetos con esclerosis múltiple recidivante-remitente activa The primary objective of the study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (P...

• Country None
• organs None
• Specialty None

An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA203 To determine the safety and durability of efficacy response of long-term treatment with BG9924 when administered with a stable dose of methotrexate (MTX) to subjects with rheumatoid arthritis (RA) who...

• Country None
• organs None
• Specialty None

Immunogenicity and Safety Study of Natalizumab (BG00002) administered to Participants with Relapsing Multiple Sclerosis The primary objective of this study is to evaluate the immunogenicity of natalizumab 300 mg SC administered to subjects with relapsing MS.

• Country None
• organs None
• Specialty None

Efficacy and Safety of BIIB074 in Participants with Trigeminal Neuralgia Placebem kontrolované, dvojitě zaslepené, randomizované, vyřazovací klinické hodnocení fáze 3 posuzující účinnost a bezpečnost přípravku BIIB074 u pacientů s neuralgií trigeminu The primary objective of the study is to evaluate the efficacy of BIIB074 in treating pain experienced by subjects with TN. The primary objective of the LTE phase of the study is to evaluate the lo...

• Country None
• organs None
• Specialty None

A Follow-Up Study to Look at Long-Term Responses in Subjects who previously took part in Study 215ON201 The primary objective of the study is to assess full-field visual evoked potential (FF-VEP) latency in subjects who were enrolled in Study 215ON201 at 2 years (+ up to 12 months) after the last study ...

• Country None
• organs None
• Specialty None